Abstract
ObjectiveBalancing bleeding risk and stroke risk in patients with atrial fibrillation (AF) is a common challenge. Though several bleeding risk scores exist, most have not included patients on direct oral anticoagulants (DOACs). We aimed at developing a novel bleeding risk score for patients with AF on oral anticoagulants (OAC) including both vitamin K antagonists (VKA) and DOACs. MethodsWe included patients with AF on OACs from a prospective multicenter cohort study in Switzerland (SWISS‐AF). The outcome was time to first bleeding. Bleeding events were defined as major or clinically relevant non‐major bleeding. We used backward elimination to identify bleeding risk variables. We derived the score using a point score system based on the β‐coefficients from the multivariable model. We used the Brier score for model calibration (<0.25 indicating good calibration), and Harrel's c‐statistics for model discrimination. ResultsWe included 2147 patients with AF on OAC (72.5% male, mean age 73.4 ± 8.2 years), of whom 1209 (56.3%) took DOACs. After a follow‐up of 4.4 years, a total of 255 (11.9%) bleeding events occurred. After backward elimination, age > 75 years, history of cancer, prior major hemorrhage, and arterial hypertension remained in the final prediction model. The Brier score was 0.23 (95% confidence interval [CI] 0.19–0.27), the c‐statistic at 12 months was 0.71 (95% CI 0.63–0.80). ConclusionIn this prospective cohort study of AF patients and predominantly DOAC users, we successfully derived a bleeding risk prediction model with good calibration and discrimination.
Highlights
Atrial fibrillation (AF), the most common arrhythmia, is associated with increased risk for cardiac thromboembolism [1]
Thromboembolism and stroke risk can be greatly reduced if oral anticoagulants (OAC, including both vitamin K antagonists 8 (VKA) and direct oral anticoagulants (DOAC)) are administered, but this treatment increases bleeding risk [4] [5]
Given the limitations of existing scores and the need for better prediction tools for patients on DOAC, we developed and internally validated a novel clinical prediction score for patients with AF who were treated with either VKA or DOAC based on data from a prospective cohort study with adjudicated clinical outcomes
Summary
Balancing bleeding risk and stroke risk in patients with atrial fibrillation (AF) is a common challenge. Though several bleeding risk scores exist, most have not included patients on direct oral anticoagulants (DOAC). We aimed at developing a novel bleeding risk score for patients with AF on oral anticoagulants (OAC) including both, vitamin K antagonists (VKA) and DOACs
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.